| Autor: |
Marija, Denčić Fekete, Milica, Komnenić Radovanović, Vojin, Vuković, Vladimir, Otašević, Sofija, Sarac, Senka, Sanader, Jelica, Jovanović, Andrej, Pešić, Darko, Antić |
| Předmět: |
|
| Zdroj: |
Genetics & Applications; 2024 Special Issue, p9-9, 1p |
| Abstrakt: |
Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are lymphoproliferative neoplasms in which genetic testing plays a very important role in determining a precise prognosis and selecting a targeted therapy. Over the past three decades, a significant development of genetic methods has taken place, which has contributed to the discovery of a large number of biomarkers in these diseases. Along with the understanding of CLL and MM pathogenesis, the development of highly effective therapeutics took place in the field of pharmacogenomics, which are used today with great success for the treatment of these hematological diseases. In CLL, the first research in the field of genetics involved the application of the standard cytogenetic method, which was successfully replaced by the fluorescent in situ hybridization (FISH) method at the end of the 1990s. Further, diagnostics developed in the direction of the application of sequencing methods, which proved to be the most sensitive for the detection of certain gene variants. However, despite the application of modern methods, cytogenetic testing in CLL has gained importance in recent years, thanks to newly discovered mitogens that initiated cell division in the vast majority of B-CLL lymphocytes. In MM, the FISH technique is still considered the gold standard for the detection of recurrent aberrations, although even with this method there are limitations in terms of the impossibility of detecting gene variants. Patients with CLL and MM can have multiple changes in the genome, which can be an additional challenge for setting a precise prognosis of the disease. Today, it is of the greatest importance to choose a sufficiently sensitive genetic method that will enable the detection of a possible relapse after the applied therapy or to assess the minimal residual disease after the patients achieve clinical remission. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
